TDY Forensic analysis

Trading Setup & Entry Strategy

TDY is currently navigating a corrective phase, having breached its 50-day SMA ($634.47). With the stock at $606.45, it is approaching the 200-day SMA support at $580.54, which represents the primary line of defense for the long-term trend.

• >Entry Zone: $580.00 - $590.00. We look to accumulate near the 200-day SMA, which has historically acted as a floor.
• >Stop Loss: $568.00 (Hard). A breach below the 200-day SMA signals a structural trend breakdown.
• >Position Sizing: 3% of portfolio.
• >Scaling: Enter 50% at $590, add 50% at $580.
• >Take Profit: $635 (50-day SMA retest), then $660 (Bollinger Upper Band).
• >Risk/Reward: ~1:2.8.

Recent Material Events (8-K Analysis)

Recent filings (April 2026) focus on executive compensation and corporate governance amendments, reflecting routine administrative actions. No material adverse events were disclosed. The company remains focused on aggressive R&D and integration of 2026 acquisitions (e.g., DD-Scientific).

Financial Health

• >Revenue Quality: Strong. Revenue grew 7.6% YoY to $1.56B in Q1 2026. Operating income rose 13.5%.
• >Cash Position: Solid, with $521.4M in cash. Successfully repaid $450M in Senior Notes post-quarter, deleveraging the balance sheet.
• >Forensic Flags: None. The company continues to show discipline in R&D spend and successful integration of past M&A.

Technical Analysis & Trade Timing

• >Status: The stock is currently in a BEARISH_CROSSING phase with RSI at 37.87. While momentum is negative, it is rapidly approaching oversold conditions. The price is trading below all major SMAs (5, 10, 50-day), confirming a short-term trend reversal.
• >Reconciliation: While fundamentals are solid (strong defense backlog, diverse segments), the technicals indicate a "value trap" risk if bought here. Wait for the 200-day SMA ($580.54) test.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days)
• >Strategy: Wait for the test of the 200-day SMA. If price holds support, initiate a long position. If price fails to hold, remain flat.

One-Liner Thesis: Teledyne exhibits robust fundamental growth and a strong defense backlog, but current technical weakness suggests a patient entry near the 200-day SMA support is optimal.